Federal Supply Schedule 36F79721D0170
Award Date 6/1/21
Last Date to Order 5/31/27
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- This Blanket Purchase Agreement (BPA), awarded to BioMarin Pharmaceutical Inc. on October 15, 2021, establishes a framework for the supply of Palynziq (pegvaliase-pqpz) to the Veterans Affairs (VA) system through the GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract carries a ceiling value of $151,685 and extends through October 14, 2026, with performance conducted from BioMarin's location in Novato, California. The award was made as a single-award, non-set-aside procurement under...
- The National Acquisition Center established a Blanket Purchase Agreement with UCB, Inc. (doing business as UCB Pharma, Inc.) on October 31, 2025, with a ceiling of $3,836,045.45 and an ultimate completion date of October 30, 2026, against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA covers Fintepla and Zilbrysq, with a product addition of Kygevvi, and incorporates 2026 Public Law pricing updates. Performance is nationwide, serving the Department of Veterans...
- GSA issued a Federal Supply Schedule contract to Biogen U.S. Corporation on September 15, 2018, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule with a ceiling value of $1.464 billion and ultimate completion date of September 14, 2026. This is a multiple-award catalog vehicle; federal agencies place delivery orders against Biogen's price list without conducting new competitions. Biogen is approved to supply drugs and pharmaceuticals under this schedule. Place of performance is Cambridge,...
- The Department of Veterans Affairs issued a Federal Supply Schedule contract to Ionis Pharmaceuticals, Inc. under Schedule 65 I B (Drugs, Pharmaceuticals, & Hematology Related Products) on August 15, 2025, with a ceiling value of $225,000.00 and performance through August 14, 2030. This is a multiple-award schedule vehicle; agencies place orders against the contractor's price list for pharmaceutical and hematology-related products rather than conducting individual competitions. The...
- The Department of Veterans Affairs issued a Federal Supply Schedule contract to Genzyme Corporation, doing business as Sanofi Genzyme, for the Pharmaceuticals and Drugs schedule (FSS-61-IB) on May 15, 2019, with a ceiling of $659.7 million. This is a multiple award schedule vehicle that allows VA and other federal agencies to place delivery orders against Genzyme's pre-established price list for pharmaceutical products, enabling streamlined procurement without competitive re-bidding on...
- This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 to PTC Therapeutics, Inc., a for-profit organization, for pharmaceuticals and drugs under GSA Schedule 65 IB. The contract has a potential value of $3 million with a period of performance through February 2024. A Blanket Purchase Agreement against this contract was also awarded to PTC Therapeutics for $500,000, running through November...
- GSA awarded a Federal Supply Schedule contract to Patriot Pharmaceuticals LLC under the Pharmaceuticals and Drugs schedule (FSS-61-IB) effective January 1, 2023, with a contract ceiling of $23.177 million through December 31, 2027. The contractor holds approval under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products. The contract carries no set-aside designation and is part of GSA's multiple-award schedule vehicle, permitting agencies to place orders against the...
- GSA issued a Federal Supply Schedule contract to Biocryst Pharmaceuticals Inc. under the Pharmaceuticals and Drugs schedule (FSS-61-IB) on May 15, 2021, with an ultimate completion date of November 15, 2026, and a ceiling value of $1.25 million. The contract is a multiple-award vehicle through which agencies place delivery orders against Biocryst's price list for pharmaceutical products. Biocryst specializes in small-molecule drugs for rare diseases, with primary federal offerings of ORLADEYO...
- GSA awarded a Federal Supply Schedule contract to Averitas Pharma, Inc. under the Pharmaceuticals and Drugs schedule (FSS-61-IB) on September 29, 2025, effective through September 28, 2030, with a contract ceiling of $19.239 million. The contractor is approved under Special Item Number 65 I B for drugs, pharmaceuticals, and hematology-related products. The award carries no set-aside designation and is part of GSA's multiple-award schedule vehicle, which allows agencies to place orders directly...
- GSA issued a Federal Supply Schedule contract to NS Pharma, Inc. under the Pharmaceuticals and Drugs schedule (FSS-61-IB), Special Item Number 65IB, effective March 15, 2021, with a ceiling value of $225,000.00 and final completion date of March 14, 2027. The contract covers drugs, pharmaceuticals, and hematology-related products and is available to federal agencies on a multi-award basis. NS Pharma maintains a commercial small business subcontracting plan under this schedule. Veterans...
Name | Description | Awardee | Potential Value | AwardDate | LastDateToOrder | Updated At |
|---|---|---|---|---|---|---|
36F79721D0170-36E79722A0004 | Biomarin Pharmaceutical Inc. | $151.7k | 10/15/21 | 10/14/26 | 12/11/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order 36F79721D0170-36C25921F0394 | Biomarin Pharmaceutical Inc. | $0 | 7/29/21 | 7/29/21 | 1/4/23 | |
BPA Call 36E79722A0004-36C26322N0466 | Biomarin Pharmaceutical Inc. | $117.4k | 2/4/22 | 9/30/22 | 2/13/24 | |
Delivery Order 36F79721D0170-36C25922F0039 | Biomarin Pharmaceutical Inc. | $0 | 10/13/21 | 10/20/21 | 2/15/23 |